<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03959423</url>
  </required_header>
  <id_info>
    <org_study_id>CIP321</org_study_id>
    <nct_id>NCT03959423</nct_id>
  </id_info>
  <brief_title>Safety Evaluation of the Advanced Hybrid Closed Loop (AHCL) System</brief_title>
  <official_title>Safety Evaluation of the Advanced Hybrid Closed Loop (AHCL) System in Type 1 Adult and Pediatric Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Diabetes</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Diabetes</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a Safety Evaluation of the Advanced Hybrid Closed Loop (AHCL) System in Type 1&#xD;
      Adult and Pediatric Subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to evaluate the safety of the Advanced Hybrid Closed Loop system&#xD;
      (AHCL) in type 1 diabetes adult and pediatric subjects in a home setting. The main objective&#xD;
      in conducting this research is to collect data from patients who use the AHCL system at home,&#xD;
      at work, at school and everywhere else.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 24, 2019</start_date>
  <completion_date type="Anticipated">May 15, 2022</completion_date>
  <primary_completion_date type="Actual">March 17, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in HbA1c</measure>
    <time_frame>3 months</time_frame>
    <description>The overall mean difference of the change in HbA1c from baseline to end of 3-month study period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in percentage of Euglycemia</measure>
    <time_frame>3 months</time_frame>
    <description>The overall mean change in % of time in euglycemia (70-180 mg/dL) from baseline to the end of study will be estimated.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Severe Hypoglycemic Event</measure>
    <time_frame>3 months</time_frame>
    <description>Number of severe hypoglycemic events occurred during 3-month period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Diabetic Ketoacidosis (DKA) Event</measure>
    <time_frame>3 months</time_frame>
    <description>Number of Diabetic Ketoacidosis (DKA) event occurred during 3-month period</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">288</enrollment>
  <condition>Type 1 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Subjects 7-75 years of age</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects who have been diagnosed with type 1 diabetes</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>AHCL insulin pump system</intervention_name>
    <description>Advanced Hybrid Closed Loop insulin pump with associated CGM and blood glucose meter</description>
    <arm_group_label>Subjects 7-75 years of age</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject is age 7-75 years at time of Screening&#xD;
&#xD;
          2. Subjects 14-75 years of age: A clinical diagnosis of type 1 diabetes for 2 years or&#xD;
             more as determined via medical record or source documentation by an individual&#xD;
             qualified to make a medical diagnosis&#xD;
&#xD;
          3. Subjects 7-13 years of age: A clinical diagnosis of type 1 diabetes for 1 year or more&#xD;
             as determined via medical record or source documentation by an individual qualified to&#xD;
             make a medical diagnosis Study-specific inclusion criteria&#xD;
&#xD;
          4. Subject is willing to perform ≥ 4 finger stick blood glucose measurements daily&#xD;
&#xD;
          5. Subject is willing to perform required sensor calibrations&#xD;
&#xD;
          6. Subject is willing to wear the system continuously throughout the study&#xD;
&#xD;
          7. Subject must have a minimum daily insulin requirement (Total Daily Dose) of greater&#xD;
             than or equal to 8 units&#xD;
&#xD;
          8. Subject has a Glycosylated hemoglobin (HbA1c) less than 10% (as processed by Central&#xD;
             Lab) at time of Screening visit Note: All HbA1c blood specimens will be sent to and&#xD;
             tested by a NGSP certified Central Laboratory. HbA1c testing must follow National&#xD;
             Glycohemoglobin Standardization Program (NGSP) standards.&#xD;
&#xD;
          9. Subject has TSH in the normal range OR if the TSH is out of normal reference range the&#xD;
             Free T3 is below or within the lab's reference range and Free T4 is within the normal&#xD;
             reference range.&#xD;
&#xD;
         10. Pump therapy for greater than 6 months prior to screening (with or without CGM&#xD;
             experience)&#xD;
&#xD;
         11. Subject must have a companion or caregiver available at night for the duration of the&#xD;
             study period who resides (or will live) in in the same building (or home). A companion&#xD;
             or caregiver should also be available during exercise challenges in the same building,&#xD;
             home or location (if not at home). This requirement may be verified by subject report&#xD;
             at screening visit.&#xD;
&#xD;
         12. Subject willing to upload data from the study pump, must have Internet access and a&#xD;
             computer system that meets the requirements for uploading the study pump&#xD;
&#xD;
         13. If subject has celiac disease, it has been adequately treated as determined by the&#xD;
             investigator&#xD;
&#xD;
         14. Subject is willing to take one of the following insulins and can financially support&#xD;
             the use of either of the 2 insulin preparations throughout the course of the study&#xD;
             (i.e. co-payments for insulin with insurance or able to pay full amount)&#xD;
&#xD;
               -  Humalog™* (insulin lispro injection)&#xD;
&#xD;
               -  NovoLog™* (insulin aspart)&#xD;
&#xD;
         15. Subjects with history of cardiovascular event 1 year or more from the time of&#xD;
             screening must have an EKG within 6 months prior to screening or during screening. If&#xD;
             subject has an abnormal EKG, participation is allowed if there is clearance from a&#xD;
             cardiologist&#xD;
&#xD;
         16. Subjects with the 3 or more cardiovascular risk factors listed below must have an EKG&#xD;
             within 6 months prior to screening or during screening. If subject has an abnormal&#xD;
             EKG, participation is allowed if there is clearance from a cardiologist&#xD;
&#xD;
             a. Cardiovascular risk factors include:&#xD;
&#xD;
               -  Age &gt;35 years&#xD;
&#xD;
               -  Type 1 diabetes of &gt;15 years' duration&#xD;
&#xD;
               -  Presence of any additional risk factor for coronary artery disease&#xD;
&#xD;
               -  Presence of microvascular disease (proliferative retinopathy or nephropathy,&#xD;
                  including microalbuminuria)&#xD;
&#xD;
               -  Presence of peripheral vascular disease&#xD;
&#xD;
               -  Presence of autonomic neuropathy&#xD;
&#xD;
         17. Subjects with history of cardiovascular event 1 year or more from the time of&#xD;
             screening must have a stress test within 6 months prior to screening or during run in&#xD;
             period. If subject fails stress test, participation is allowed if there is clearance&#xD;
             from a cardiologist&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject has a history of 1 or more episodes of severe hypoglycemia, which resulted in&#xD;
             any the following during the 6 months prior to Screening:&#xD;
&#xD;
               1. Medical assistance (i.e. Paramedics, Emergency Room (ER) or Hospitalization)&#xD;
&#xD;
               2. Coma&#xD;
&#xD;
               3. Seizures&#xD;
&#xD;
          2. Subject has been hospitalized or has visited the ER in the 6 months prior to Screening&#xD;
             resulting in a primary diagnosis of uncontrolled diabetes&#xD;
&#xD;
          3. Subject has had Diabetic Ketoacidosis (DKA) in the 6 months prior to Screening.&#xD;
&#xD;
          4. Subject has Hypoglycemia Unawareness, as measured by the Gold questionnaire (Gold,&#xD;
             MacLeod et al. 1994) at Screening&#xD;
&#xD;
          5. Subject is unable to tolerate tape adhesive in the area of sensor placement&#xD;
&#xD;
          6. Subject has any unresolved adverse skin condition in the area of sensor placement&#xD;
             (e.g., psoriasis, dermatitis herpetiformis, rash, Staphylococcus infection)&#xD;
&#xD;
          7. Women of child-bearing potential who have a positive pregnancy test at Screening or&#xD;
             plan to become pregnant during the course of the study&#xD;
&#xD;
          8. Females who are sexually active and able to conceive will be excluded if they are not&#xD;
             using an effective method of contraception and do not agree to continue using an&#xD;
             effective method of contraception for the duration of the study as determined by&#xD;
             investigator.&#xD;
&#xD;
          9. Subject has had any of the following cardiovascular events within 1 year of screening:&#xD;
             myocardial infarction, unstable angina, coronary artery bypass surgery, coronary&#xD;
             artery stenting, transient ischemic attack, cerebrovascular accident, angina,&#xD;
             congestive heart failure, ventricular rhythm disturbances or thromboembolic disease&#xD;
&#xD;
         10. Subject is being treated for hyperthyroidism at time of Screening&#xD;
&#xD;
         11. Subject has a diagnosis of adrenal insufficiency&#xD;
&#xD;
         12. Subject has taken any oral, injectable, or intravenous (IV) glucocorticoids within 8&#xD;
             weeks from time of Screening, or plans to take any oral, injectable, or IV&#xD;
             glucocorticoids during the course of the study&#xD;
&#xD;
         13. Subject is actively participating in an investigational study (drug or device) wherein&#xD;
             he/she has received treatment from an investigational study drug or investigational&#xD;
             study device in the last 2 weeks&#xD;
&#xD;
         14. Subject is currently abusing illicit drugs&#xD;
&#xD;
         15. Subject is currently abusing marijuana&#xD;
&#xD;
         16. Subject is currently abusing prescription drugs&#xD;
&#xD;
         17. Subject is currently abusing alcohol&#xD;
&#xD;
         18. Subject is using pramlintide (Symlin), DPP-4 inhibitor, liraglutide (Victoza or other&#xD;
             GLP-1 agonists), metformin, canagliflozin (Invokana or other SGLT2 inhibitors) at time&#xD;
             of Screening&#xD;
&#xD;
         19. Subject has a history of visual impairment which would not allow subject to&#xD;
             participate in the study and perform all study procedures safely, as determined by the&#xD;
             investigator&#xD;
&#xD;
         20. Subject has elective surgery planned that requires general anesthesia during the&#xD;
             course of the study&#xD;
&#xD;
         21. Subject has a sickle cell disease, hemoglobinopathy; or has received red blood cell&#xD;
             transfusion or erythropoietin within 3 months prior to time of Screening&#xD;
&#xD;
         22. Subject plans to receive red blood cell transfusion or erythropoietin over the course&#xD;
             of study participation&#xD;
&#xD;
         23. Subject diagnosed with current eating disorder such as anorexia or bulimia&#xD;
&#xD;
         24. Subject has been diagnosed with chronic kidney disease that results in chronic anemia&#xD;
&#xD;
         25. Subject has a hematocrit that is below the normal reference range of lab used.&#xD;
&#xD;
         26. Subject is on dialysis&#xD;
&#xD;
         27. Subject has serum creatinine of &gt;2 mg/dL.&#xD;
&#xD;
         28. Research staff involved with the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Arkansas Diabetes and Endocrinology Center</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scripps Whittier Diabetes Institute</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SoCal Diabetes</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diablo Clinical Research</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94598</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barbara Davis Center - Adults</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barbara Davis Center - Pediatric</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale Diabetes Research Program</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta Diabetes Associates</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30318</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southeastern Endocrine</name>
      <address>
        <city>Roswell</city>
        <state>Georgia</state>
        <zip>30076</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Diabetes Center</name>
      <address>
        <city>Idaho Falls</city>
        <state>Idaho</state>
        <zip>83404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>International Diabetes Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55416</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AM Diabetes &amp; Endocrinology Center</name>
      <address>
        <city>Bartlett</city>
        <state>Tennessee</state>
        <zip>38133</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Endocrinology</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78681</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diabetes and Glandular Disease Clinic</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rainier Clinical Research</name>
      <address>
        <city>Renton</city>
        <state>Washington</state>
        <zip>98057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital and Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>May 20, 2019</study_first_submitted>
  <study_first_submitted_qc>May 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 22, 2019</study_first_posted>
  <last_update_submitted>November 17, 2021</last_update_submitted>
  <last_update_submitted_qc>November 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

